FDA advisory highlights supplement excipient
This article was originally published in The Tan Sheet
One lot of crospovidone from Chinese firm Tianjin Boai NKY International contains peroxide levels more than four times higher than the maximum set by global standards, FDA says Oct. 21. Although not a significant health risk, the peroxide could cause a loss of potency in dietary supplements and pharmaceuticals that use crospovidone and other providone analogues, the agency says. Daniel Fabricant, VP of scientific and regulatory affairs for the Natural Products Association, said the excipient aids dissolution in tablets and softgels, and the high peroxide levels likely signal ingredients past their shelf life expiry. FDA's advisory reminds supplement makers "it's another spec they need to be looking for" in their excipients, Fabricant said
You may also be interested in...
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.
India is allowing importers and manufacturers of certain devices – for whom new licensing requirements came into effect on 1 January – to continue marketing their products for six months if they have already applied for a license. See what Rajiv Nath from the Association of Indian Medical Device Industry (AiMeD) said about it here.